Clinical Trial Results:
An Exploratory Study to Determine Potential Predictive Markers of Response and/or
Toxicity in Patients with Unresectable Stage III or IV Malignant Melanoma Randomized and Treated with Ipilimumab (MDX-010/BMS-734016) at Two Dose Levels.
Revised Protocol 4 dated 07-Jul-2006 incorporating Protocol Amendments 02, 03, 04 & 05.
+ Protocol Amendment 1 dated 20-Jul-2005
Summary
|
|
EudraCT number |
2005-002126-64 |
Trial protocol |
NO SE DK IT |
Global completion date |
11 Oct 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Dec 2016
|
First version publication date |
07 Dec 2016
|
Other versions |
|
Summary report(s) |
CA184-004_Synopsis CA184-004_Synopsis_Addendum |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.